Top

Published in:

01-09-2018 | Pulmonology and Respiratory Care (D Breen, Section Editor)

Tailoring Treatment in Obstructive Lung Disease: Asthma, COPD, Asthma/COPD Overlap and Eosinophilic COPD

Authors: Joseph Walsh, Andrew Scott, Robert Rutherford

Published in: Current Geriatrics Reports | Issue 3/2018

Abstract

Obstructive lung disease exacts a huge global health burden with a high prevalence of both asthma and COPD in elderly patients.

Purpose of Review

This review is to update the general and elderly care physician on diagnosis and management of COPD and asthma and the recently established disease asthma/COPD overlap (ACO) and the particular challenges treating obstructive lung disease in elderly patients.

Recent Findings

COPD pharmacology has changed considerably in the last decade with a dramatic increase in the utility of single and dual long-acting bronchodilators both for symptom and exacerbation attenuation. The emergence of ACO and the COPD phenotype eosinophilic COPD also appear to require nuanced therapeutic approaches. There is also a strong emphasis now on screening and treating comorbid conditions in COPD. In asthma the emergence of tailored therapy for different severe asthma phenotypes is also discussed.

Summary

Obstructive lung diseases are very common in elderly patients and both diagnosis and treatment of these conditions is more challenging than in younger patients.

Asthma GIf. Global Strategy for asthma management and prevention, 2018. 2018.

Burgess JA, Matheson MC, Gurrin LC, Byrnes GB, Adams KS, Wharton CL, et al. Factors influencing asthma remission: a longitudinal study from childhood to middle age. Thorax. 2011;66(6):508–13. https://doi.org/10.1136/thx.2010.146845.CrossRefPubMed

Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. https://doi.org/10.7189/jogh.05-020415.CrossRefPubMedPubMedCentral

Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32. https://doi.org/10.1183/09031936.06.00124605.CrossRefPubMed

Disease GIfCOL. Global STRATEGY for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). 2018.

Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–42. https://doi.org/10.1016/s2213-2600(15)00106-x.CrossRefPubMed

Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9):1016–27. https://doi.org/10.1164/rccm.201303-0437ST.CrossRefPubMed

Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309–29. https://doi.org/10.1164/ajrccm.161.1.ats11-99.CrossRefPubMed

Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, et al. Indirect airway challenges. Eur Respir J. 2003;21(6):1050–68.CrossRefPubMed

10.

Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2009;123(3):519–28. https://doi.org/10.1016/j.jaci.2009.01.061. quiz 29-30CrossRefPubMed

11.

Network BTSSIG. SIGN 153 British guideline on the management of asthma. 2016.

12.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):Cd003559. https://doi.org/10.1002/14651858.CD003559.pub4

13.

Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16. https://doi.org/10.1111/j.1398-9995.2004.00772.x.CrossRefPubMed

14.

NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 278. Omalizumab for treating severe persistent allergic asthma. 2013.

15.

• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207. https://doi.org/10.1056/NEJMoa1403290. This was a tremendous breakthrough in severe asthma care as previously only atopic subjects could benefit from targeted therapy. CrossRefPubMed

16.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97. https://doi.org/10.1056/NEJMoa1403291.CrossRefPubMed

17.

Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. https://doi.org/10.1016/s2213-2600(15)00042-9.CrossRefPubMed

18.

Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90. https://doi.org/10.1016/s2213-2600(14)70201-2.CrossRefPubMed

19.

NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 479. Reslizumab for treating severe eosinophilic asthma. 2017.

20.

NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 431. Mepolizumab for treating severe refractory eosinophilic asthma. 2017.

21.

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573–81. https://doi.org/10.2147/copd.s16975.PubMedPubMedCentralCrossRef

22.

Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009;64(10):894–900. https://doi.org/10.1136/thx.2008.110619.CrossRefPubMedPubMedCentral

23.

Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–33. https://doi.org/10.1378/chest.10-2948.CrossRefPubMedPubMedCentral

24.

Lokke A, Ulrik CS, Dahl R, Plauborg L, Dollerup J, Kristiansen LC, et al. Detection of previously undiagnosed cases of COPD in a high-risk population identified in general practice. COPD. 2012;9(5):458–65. https://doi.org/10.3109/15412555.2012.685118.CrossRefPubMed

25.

Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–52.CrossRefPubMedPubMedCentral

26.

Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–22. https://doi.org/10.1164/ajrccm.157.5.9709032.CrossRefPubMed

27.

Labonte LE, Tan WC, Li PZ, Mancino P, Aaron SD, Benedetti A, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194(3):285–98. https://doi.org/10.1164/rccm.201509-1795OC.CrossRefPubMed

28.

Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2008;(2):Cd000165. https://doi.org/10.1002/14651858.CD000165.pub3.

29.

Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772–8. https://doi.org/10.1136/thx.2006.060145.CrossRefPubMedPubMedCentral

30.

Katajisto M, Koskela J, Lindqvist A, Kilpeläinen M, Laitinen T. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations. Respir Med. 109(10):1320–5. https://doi.org/10.1016/j.rmed.2015.08.001.

31.

Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, et al. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med. 2015;192(11):1373–86. https://doi.org/10.1164/rccm.201510-1966ST.CrossRefPubMed

32.

Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147(4):894–942. https://doi.org/10.1378/chest.14-1676.CrossRefPubMed

33.

Berlin I. Endocrine and metabolic effects of smoking cessation. Curr Med Res Opin. 2009;25(2):527–34.CrossRefPubMed

34.

Ninot G. Anxiety and depression in COPD: a review. Rev Mal Respir. 2011;28(6):739–48. https://doi.org/10.1016/j.rmr.2010.11.005.CrossRefPubMed

35.

Zeller A. Medical therapy for smoking cessation. Ther Umschau Rev Ther. 2010;67(8):419–25. https://doi.org/10.1024/0040-5930/a000074.CrossRef

36.

Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis. 2008;3(1):45–53.CrossRefPubMedPubMedCentral

37.

Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence. 2010;4:355–62.CrossRefPubMedPubMedCentral

38.

Britton J, Arnott D, McNeill A, Hopkinson N. Nicotine without smoke-putting electronic cigarettes in context. BMJ. 2016;353:i1745. https://doi.org/10.1136/bmj.i1745.CrossRefPubMed

39.

Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89. https://doi.org/10.1056/NEJMoa063070.CrossRefPubMed

40.

•• Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34. https://doi.org/10.1056/NEJMoa1516385. This was a seminal paper in COPD care demonstrating greater symptom and exacerbation control with a LABA/ LAMA compared to ICS/LABA in exacerbating patients with an FEV1 <60% predicted. CrossRefPubMed

41.

Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir. 2013;22(1):92–100. https://doi.org/10.4104/pcrj.2012.00092.CrossRef

42.

Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–37. https://doi.org/10.1183/09031936.00128914.CrossRefPubMed

43.

Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98. https://doi.org/10.1056/NEJMoa1104623.CrossRefPubMedPubMedCentral

44.

Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503–8. https://doi.org/10.1164/rccm.201402-0207OC.CrossRefPubMedPubMedCentral

45.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet (London, England). 2015;385(9971):857–66. https://doi.org/10.1016/s0140-6736(14)62410-7.CrossRef

46.

Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017;196(12):1535–43. https://doi.org/10.1164/rccm.201707-1327OC.CrossRefPubMed

47.

Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015;313(9):936–48. https://doi.org/10.1001/jama.2015.1175.CrossRefPubMed

48.

Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64(8):728–35. https://doi.org/10.1136/thx.2008.108027.CrossRefPubMed

49.

Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpelainen M, Kinnula VL, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011;48(3):279–85. https://doi.org/10.3109/02770903.2011.555576.CrossRefPubMed

50.

Anzueto A, Miravitlles M. Considerations for the correct diagnosis of chronic obstructive pulmonary disease and its management with bronchodilators. Chest. 2018; https://doi.org/10.1016/j.chest.2018.02.023.

51.

Kolsum U, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017;18(1):73. https://doi.org/10.1186/s12931-017-0559-0.CrossRefPubMedPubMedCentral

52.

Perng DW, Huang HY, Chen HM, Lee YC, Perng RP. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest. 2004;126(2):375–81. https://doi.org/10.1378/chest.126.2.375.CrossRefPubMed

53.

Leigh R, Pizzichini MMM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–71.CrossRefPubMed

54.

Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–71. https://doi.org/10.1164/rccm.201104-0597OC.CrossRefPubMed

55.

Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–74. https://doi.org/10.1164/rccm.201509-1869OC.CrossRefPubMed

56.

Couillard S, Larivee P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–73. https://doi.org/10.1016/j.chest.2016.10.003.CrossRefPubMed

57.

Barnes NC, Sharma R, Lettis S, Calverley PMA. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374–82. https://doi.org/10.1183/13993003.01370-2015.CrossRefPubMed

58.

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94. https://doi.org/10.1056/NEJMoa1407154.CrossRefPubMed

59.

Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–29. https://doi.org/10.1056/NEJMoa1708208.CrossRefPubMed

60.

Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122. https://doi.org/10.1186/1465-9921-11-122.CrossRefPubMedPubMedCentral

61.

Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Investig. 2014;44(1):93–102. https://doi.org/10.1111/eci.12181.CrossRef

62.

Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099–107. https://doi.org/10.1378/chest.128.4.2099.CrossRefPubMed

63.

Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–12. https://doi.org/10.1183/09031936.00114307.CrossRefPubMed

64.

Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38. https://doi.org/10.1056/NEJMoa0909883.CrossRefPubMed

65.

O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55(8):635–42.CrossRefPubMedPubMedCentral

66.

Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med. 1995;151(1):82–6. https://doi.org/10.1164/ajrccm.151.1.7812577.CrossRefPubMed

Title: Tailoring Treatment in Obstructive Lung Disease: Asthma, COPD, Asthma/COPD Overlap and Eosinophilic COPD
Authors: Joseph Walsh
Andrew Scott
Robert Rutherford
Publication date: 01-09-2018
Publisher: Springer US
Published in: Current Geriatrics Reports / Issue 3/2018
Electronic ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-018-0253-1

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Diffuse Parenchymal Lung Diseases in the Elderly

Muscle Wasting in the Hospitalised COPD Patients—How Can it Be Prevented and Treated?

Mediterranean Diet to Promote Healthy Aging

Malignant Pleural Effusions—Personalised Management

Endobronchial Ultrasound (EBUS) for Staging Lung Cancer in the Elderly Population—Specific Procedural and Medication Issues

Implementing Medical Nutritional Therapy Through Dietary Patterns in Prevention and Treatment of Diabetes

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage